Every 10-Q that CapsoVision, Inc. (CV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CV filings page.
CapsoVision, Inc. develops capsule endoscopy and AI-based imaging solutions for gastrointestinal diagnostics, led by its CapsoCam Plus small-bowel capsule and in-development CapsoCam Colon and CapsoCam UGI systems. For the quarter ended June 30, 2026, net revenue was $3.64 million versus $3.32 million a year earlier, while the operating loss widened to $7.58 million from $4.65 million. For the first six months of 2026, revenue was $6.44 million and net loss was $14.51 million.
Cash and cash equivalents were $9.08 million as of June 30, 2026, after using $14.47 million in net cash for operating activities in the first half. The company raised approximately $14 million of gross proceeds in a March 2026 private placement of 2,867,089 common shares at $4.883 per share, and later put in place a $100 million at-the-market equity program with a sales agent. Management states that, despite these financings, there is substantial doubt about its ability to continue as a going concern within one year without additional capital.
The pipeline includes a second-generation CapsoCam Colon capsule, with a pivotal study of 801 patients completed and a 510(k) submission targeted for the fourth quarter of 2026, and AI enhancements to CapsoCam Plus, for which FDA clearance is anticipated by the end of the third quarter of 2026. The company is also running an early pancreatic cancer study using its CapsoCam UGI system and plans to resubmit a Breakthrough Device Designation request after additional data are collected.
CapsoVision, Inc. reported first‑quarter 2026 results showing essentially flat revenue but higher losses as it invests in product development and clinical programs. Net revenue was $2,792 thousand, compared with $2,783 thousand a year earlier, while net loss widened to $7,033 thousand from $5,375 thousand.
Operating expenses rose to $8,422 thousand, driven mainly by research and development spending of $4,435 thousand as the company advances its CapsoCam Colon and AI initiatives. A March 2026 private placement added approximately $14,000 thousand in gross proceeds, lifting cash and cash equivalents to $17,933 thousand at March 31, 2026.
Despite the capital raise, management concluded that substantial doubt exists about CapsoVision’s ability to continue as a going concern within one year, given ongoing operating losses, negative operating cash flows of $6,066 thousand for the quarter, and the need for additional financing to meet growth and innovation objectives.
CapsoVision, Inc. reported higher Q3 results but remained unprofitable. Net revenue for the three months ended September 30, 2025 was $3.538 million versus $2.966 million a year ago, with gross profit of $1.914 million. Operating expenses rose to $9.933 million, driving a quarterly net loss of $7.921 million and a nine‑month net loss of $17.921 million. Cash and cash equivalents were $17.787 million as of September 30, 2025.
The company completed an IPO in July 2025, raising approximately $23.37 million in net proceeds and converting all preferred stock into common shares after a 1‑for‑3.33 reverse split. Management disclosed that current conditions “raise substantial doubt” about the ability to continue as a going concern. CapsoVision also entered a $4.1 million development agreement with Canon for CMOS sensors, paying $1.0 million at effectiveness and carrying an outstanding purchase commitment of $2.5 million. Revenue was driven mainly by U.S. product sales, while service revenue included cloud delivery and physician reading services.
CapsoVision reported a transformative quarter highlighted by a completed IPO and continued operational challenges. The company completed an initial public offering in July 2025, selling 5,629,978 shares at $5.00 per share for gross proceeds of approximately $28.1 million and net proceeds of about $23.4 million. As of June 30, 2025, the company had approximately $1.1 million in cash and an accumulated deficit of $140.4 million. The financials for the six months ended June 30, 2025 show an operating loss of $10,033, a net loss of $10,000, and net cash used in operating activities of $9,512. Management disclosed substantial doubt about going concern.
The company executed a 1-for-3.33 reverse stock split effective July 2, 2025, converted outstanding preferred stock into common stock prior to the IPO, and increased authorized common shares to 300 million. Regulatory and product updates include a 510(k) filing for CapsoCam Colon in Q2 2025 targeting FDA clearance in early 2026 and a development agreement with Canon for CMOS sensors with up to $4.1 million in fees. Material weaknesses in internal controls were identified with remediation in progress.